Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944981 | 0.86 | CA1 (0.30) | CA1CA2CA9ALDH1A1 | |
| SCHEMBL31192819 | 0.85 | CA1 (0.32) | CA1CA2CA9ALDH1A1MEN1 | |
| SCHEMBL5704622 | 0.82 | — | — | |
| SCHEMBL604452 | 0.79 | — | — | |
| SCHEMBL14585732 | 0.79 | CA1 (0.34) | CA1CA2CA9ALDH1A1MEN1 | |
| SCHEMBL14293598 | 0.78 | CA1 (0.32) | CA1CA2CA9CA7 | |
| SCHEMBL13431908 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8383218 | 0.75 | — | — | |
| SCHEMBL859268 | 0.74 | — | — | |
| SCHEMBL150377 | 0.73 | CA1 (0.37) | CA1CA2CA9ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12438194-B2 | Electrolyte systems including chalcogenides and compound containing electron withdrawing group, and electrochemical cell including the same | Lyten, Inc. (US) | 2025-10-07 | — | — | US | claimed |
| US-20250286144-A1 | ELECTROLYTE SYSTEMS INCLUDING PERFORMANCE-ENHANCING ADDITIVES, AND ELECTROCHEMICAL CELLS INCLUDING THE SAME | Lyten, Inc. | 2025-09-11 | — | — | US | claimed |
| US-20250286126-A1 | ELECTROLYTE SYSTEMS INCLUDING CHALCOGENIDES AND COMPOUND CONTAINING ELECTRON WITHDRAWING GROUP, AND ELECTROCHEMICAL CELL INCLUDING THE SAME | Lyten, Inc. | 2025-09-11 | — | — | US | claimed |
| US-20250286127-A1 | ELECTROLYTE SYSTEMS INCLUDING ELECTRON WITHDRAWING COMPOUNDS WITH AN ALPHA-BETA MOTIF FOR IMPROVING PERFORMANCE OF LITHIUM-BASED SECONDARY BATTERIES | Lyten, Inc. | 2025-09-11 | — | — | US | claimed |
| US-20250286141-A1 | ELECTROLYTE SYSTEMS INCLUDING PERFORMANCE-ENHANCING ADDITIVES, AND ELECTROCHEMICAL CELLS INCLUDING THE SAME | Lyten, Inc. | 2025-09-11 | — | — | US | claimed |
| CN-115084655-A | Electrolyte, preparation method thereof and lithium metal battery containing electrolyte | 蜂巢能源科技(无锡)有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-20260112616-A1 | ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES | LYTEN INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4711389-A1 | METHOD FOR PRODUCING AQUEOUS FLUOROPOLYMER DISPERSION, AND AQUEOUS FLUOROPOLYMER DISPERSION | Daikin Industries, Ltd. (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4707314-A2 | COMPOSITION AND METHOD FOR PRODUCING THE SAME | Daikin Industries, Ltd. (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-4026855-B1 | COMPOSITION AND METHOD FOR PRODUCING SAME | DAIKIN IND LTD (JP) | 2026-01-28 | — | — | EP | disclosed |
| EP-4685166-A2 | COMPOSITION AND METHOD FOR PRODUCING THE SAME | Daikin Industries, Ltd. (JP) | 2026-01-28 | — | — | EP | disclosed |
| US-12531269-B2 | Silicon-based energy storage devices with fluorinated electrolyte formulations | ENEVATE CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20200388882-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH FLUORINATED ELECTROLYTE FORMULATIONS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | disclosed |
| EP-0868477-B1 | FLUORINATED ONIUM SALTS, CURABLE COMPOSITIONS CONTAINING SAME, AND METHOD OF CURING USING SAME | MINNESOTA MINING & MFG (US) | 2004-08-11 | — | — | EP | disclosed |
| EP-0868477-A1 | FLUORINATED ONIUM SALTS, CURABLE COMPOSITIONS CONTAINING SAME, AND METHOD OF CURING USING SAME | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5734085-A | RELEASE AGENT FOR FLUOROPOLYMERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| WO-1997023556-A1 | FLUORINATED ONIUM SALTS, CURABLE COMPOSITIONS CONTAINING SAME, AND METHOD OF CURING USING SAME | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023490-A1 | FLUORINATED PHOSPHONIUM SALTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5591804-A | VINYLIDENE FLUORIDE POLYMER | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12531269-B2 | Silicon-based energy storage devices with fluorinated electrolyte formulations | SLC9A2, SLC9A1, HCN2 | CA1 53/4885CA2 4/4885CA9 79/4885 |
| US-20260112616-A1 | ADVANCED ELECTROLYTE SYSTEMS WITH SPECIALIZED ADDITIVES FOR IMPROVING PERFORMANCE OF LITHIUM-SULFUR BATTERIES | MEF2D, LEF1, KCNN2 | CA1 674/4885CA2 214/4885CA9 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.